Navigation Links
Frost & Sullivan Announces Cutting Edge Life Sciences Research on the Horizon
Date:3/21/2012

MOUNTAIN VIEW, Calif., March 21, 2012 /PRNewswire/ -- When deciding between the life sciences offerings of various market research organizations, the upcoming and existing research programs prove highly relevant.  To meet this need, Frost & Sullivan introduces the Life Sciences Content: Pharmaceuticals, Biotechnology, In-Vitro Diagnostics and Life Sciences Research Tools, 2010 to 2012 compendium.  This resource includes Frost & Sullivan's Life Sciences proposed key research for 2012, as well as the profiling of recent content over the last two years. 

If you are interested in receiving the complimentary Frost & Sullivan Life Sciences Content: Pharmaceuticals, Biotechnology, In-Vitro Diagnostics and Life Sciences Research Tools, 2010 to 2012  compendium, please send an email to Britni Myers, Corporate Communications, at britni.myers@frost.com, with your full name, company name, job title, telephone number, company email address, company Web site, city, state and country.

"The current trend in the pharmaceutical industry is to tackle incredibly complex disease areas with significant unmet needs," said Frost & Sullivan Life Sciences Global Program Manager Jennifer Brice.  "Taking on these challenges requires developing novel drugs and biologics to treat the diseases.  However, due to the increasing understanding of the role that heterogeneity of human and viral genomes plays in disease pathology and the likelihood of the success or failure of a drug, the 'one size fits all' model does not always work."

To address these highly varied obstacles, the compendium allows life science organizations to compare and distinguish products in the market most relevant to their needs and growth challenges.  This may prove particularly handy when a company is attempting to understand potential expansion opportunities, seeking a merger or acquisition suitable for their current requirements, or working to build a competitive landscape, among other endeavors. 

"The strategic goal of many healthcare companies is to offer or contribute to a personalized healthcare solution by producing diagnostics, instrumentation and drugs," said Brice.  "This results in a large integrated knowledge base that more easily allows for the development of targeted medicines, novel drug delivery mechanisms, patient-specific drugs and virtual patient monitoring tools.  Additionally, the convergence between pharma, biotech, life science research tools and in-vitro diagnostics allows our clients to have a comprehensive outlook of the entire life sciences industry."

Covering a wide-range of life sciences topics, this interactive compendium includes a catalogue of tentative 2012 research titles, with updates added throughout the year to reflect the most current information and offerings available.  To supply an all-encompassing viewpoint, the compendium also includes 2010 and 2011 research information.  For each of the research titles released in 2011 and 2012, the compendium provides an abstract and table of contents.  Additionally, this feature provides extensive functionality, allowing users to select a title from the table of contents and jump directly to the relevant page.      

The Life Sciences Content: Pharmaceuticals, Biotechnology, In-Vitro Diagnostics and Life Sciences Research Tools, 2010 to 2012 compendium profiles research within the global Life Sciences Growth Partnership Services program, which includes the following markets: contract outsourcing, convergence of therapeutics and diagnostics, life science research tools, next generation biologics, next generation sequencing, pharmaceutical pipelines, and vaccines.  All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.

Life Sciences Content: Pharmaceuticals, Biotechnology, In-Vitro Diagnostics and Life Sciences Research Tools, 2010 to 2012

Contact:
Britni Myers
Corporate Communications – North America
P: 210.477.8481
F: 210.348.1003
E: britni.myers@frost.com

http://www.frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Vascular Biogenics Ltd. Presented With the Frost & Sullivan 2008 European Gene Expression Targeting Platform Technology Innovation Award
2. Frost & Sullivan Recognizes Kionixs Dominance in the MEMS Accelerometers Market Through Product Line Strategy
3. ESA Receives 2008 Frost & Sullivan North American Technology Innovation Award for Development of Integrated Metabolomics Systems
4. Celsis Receives Frost & Sullivan 2008 Best Practices Award
5. Small Animal Imaging Market: Biospace Lab Wins Frost & Sullivan Accolade for Its Successful Product Line Strategy
6. Frost & Sullivan Acknowledges ISTO Technologies Role in Developing Advanced Biologic Products for Bone Healing
7. Innovation and Strong Therapeutic Potential Seen in Adult Stem Cells, According to Frost & Sullivan
8. Frost & Sullivan Awards Genpathway 2008 Healthcare Innovation Award
9. Aposense Receives Frost & Sullivan Technology Innovation of the Year Award
10. Frost & Sullivan Presents CorMatrix Cardiovascular Inc. with 2008 Healthcare Innovation Award for the Treatment of Cardiovascular Disease
11. Frost & Sullivan Awards Baxters BioPharma Solutions Business the 2008 North American Customer Service Leadership of the Year Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... CA (PRWEB) , ... October ... ... (https://www.onramp.bio/ ) has launched Rosalind™, the first-ever genomics analysis platform specifically designed ... bioinformatics complexity. Named in honor of pioneering researcher Rosalind Franklin, who made ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... pathology, announced today it will be hosting a Webinar titled, “Pathology is going ... Pathology Associates , on digital pathology adoption best practices and how Proscia improves ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh ... orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of ... SBT-100 is able to cross the cell membrane and bind intracellular STAT3 and ...
(Date:10/10/2017)... , Oct. 10, 2017 International research firm Parks ... Strategy, will speak at the TMA 2017 Annual Meeting , October ... trends in the residential home security market and how smart safety and ... Parks ... "The residential ...
Breaking Biology Technology:
(Date:4/5/2017)... 2017 KEY FINDINGS The global ... a CAGR of 25.76% during the forecast period of ... factor for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is ... geography. The stem cell market of the product is ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/30/2017)... The research team of The Hong Kong ... identification by adopting ground breaking 3D fingerprint minutiae recovery and matching ... and accuracy for use in identification, crime investigation, immigration control, security ... ... A research team led by ...
Breaking Biology News(10 mins):